Research Areas

A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine Whether, In Patients With Type 2 Diabetes at High Risk for Cardiovascular and Renal Events, An FDA Approve Medication, on Top of Conventional Treatment, Reduces Cardiovascular and Renal Morbidity and Mortality

A Double-Blind, Placebo-Controlled, Parallel Group, Dose-Response Study to Evaluate the efficacy and Safety of and Investigational Medication Versus Placebo in the Relief of Pain in Diabetic Peripheral Polyneuropathy

A Phase II Study of an Investigational Topical Medication for the Treatment of Symptomatic Diabetic Peripheral Neuropathy

A Phase II Repeat Dosing Clinical Trial of An Investigational Medication in Subjects with Moderate to Severe Diabetic Neuropathy and Unmeasurable Nerve Conduction Velocity.

A Multicenter, Randomized, Double-Blind, Placebo Controlled Study of the Effect of An Investigational Medication At Two Doses for 24 Weeks Treatment on the Rate of Regeneration of Epidermal Nerve Fibers in Patients with Mild Diabetic Peripheral Neuropathy

Efficacy and Safety of 2 mg/day of An Investigational Medication on Sleep Maintenance Insomnia with a Sub-Study of the Effect of An Investigational Medication on Stable Type II Diabetes Mellitus: A One-Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel Group, Multiple Dose Study of the Safety and Efficacy of Synthroid in Patients with Mild Thyroid Failure

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of An Investigational Medication When Co-Administered with Amlodipine 5 mg in Subjects with Essential Hypertension

An 8-Month Phase 3, Open-Label Study With a Blinded Reversal Phase to Evaluate the Safety and Tolerability of An Investigational Medication in Subjects with Essential Hypertension

Evaluation of the Safety and Efficacy of An Investigational Medication: A Dose-Ranging Study

A 12-week Randomized Double-Blind Placebo-Controlled Multicenter Trial to Evaluate the Efficacy and Safety of An Investigational Medication and Atorvastatin (10mg) in the Treatment of Subjects With Hypercholesterolemia

A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe 10mg When Added to Atorvastatin 10mg Versus Titration to Atorvastatin 20mg and to 40mg in Elderly Patients with Hypercholesterolemia at High Risk for CHD.

A Multicenter, Prospective, Longitudinal, Randomized, Double-Blind, Phase III Study to Evaluate the Efficacy and Safety of Daily Administration of Pravastatin 40mg or Fenofibrate 160 mg or An Investigational Combination Medication for 12 Weeks Followed by a 52-Week Open Label Safety Phase of the Investigational Combination Medication Alone in the Treatment of Combined Hyperlipidemia.

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of the Combination of an Investigational Medication and Atorvastatin 20mg vs. Monotherapy in Subjects With Moderate Hypercholesterolemia.

A Comparative Efficacy and Safety Study of An Investigational Medication (40 mg) and Omeprazole (20 mg) in Study Subjects with Erosive Esophagitis

A Multicenter, Randomized, Double Blind, Placebo-Controlled Trial of An Investigational Medicated Tape for Treatment of Chronic Low Back Pain

A Randomized, Double-Blind, Double-Dummy Comparison of Sulfonylurea with a Titrated Dose of and Investigational Medication in Type 2 Diabetic Patients

A Double-Blind, Randomized Study of the Effects of an Investigational Medication in Patients with Type 2 Diabetes Who Are Currently Treated with Immediate Release Metformin

A Double-Blind, Placebo-Controlled, Randomized Trial to Determine the Effects of a Range of Doses of Metformin Novel Oral Dose Form (biphasic tablet). Administered Either once or Twice a Day in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control with Diet and Exercise

A Phase 3b, randomized, open-label, parallel group, multicenter trail assessing the efficacy of Exubera vs Lispro introduced into a Lantus based regimen in suboptimally controlled patients with Type 2 Diabetes Mellitus